Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/107585
COMPARTIR / EXPORTAR:
logo share SHARE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

Invitar a revisión por pares abierta
Campo DC Valor Lengua/Idioma
dc.contributor.authorRafols, Ismael-
dc.contributor.authorHopkins, Michael M.-
dc.contributor.authorHoekman, Jarno-
dc.contributor.authorSiepel, Josh-
dc.contributor.authorO'Hare, Alice-
dc.contributor.authorPerianes-Rodríguez, Antonio-
dc.contributor.authorNightingale, Paul-
dc.date.accessioned2014-11-14T10:39:31Z-
dc.date.available2014-11-14T10:39:31Z-
dc.date.issued2012-
dc.identifier.citationDRUID Society Conference 2012-
dc.identifier.urihttp://hdl.handle.net/10261/107585-
dc.descriptionTrabajo presentado al DRUID Society Conference on Innovation and Competitiveness - Dynamics of Organizations, Industries, Systems and Regions, celebrado en Copenhague (Dinamarca) del 19 al 21 de Junio de 2012.-
dc.description.abstractThere is a widespread perception that pharmaceutical R&D is facing a productivity crisis characterised by stagnation in the numbers of new drug approvals in the face of increasing R&D costs. This study explores pharmaceutical R&D dynamics by examining the publication activities of all R&D laboratories of the major European and US pharmaceutical firms during the period 1995-2009. The empirical findings present an industry in transformation. In the first place, we observe a decline of the total number of publications by large firms. Second, we show a relative increase of their external collaborations suggesting a tendency to outsource, and a diversification of the disciplinary base, in particular towards computation, health services and more clinical approaches. Also evident is a more pronounced decline in publications by both R&D laboratories located in Europe and by firms with European headquarters. Finally, while publications by big pharma in emerging economies sharply increase, they remain extremely low compared with those in developed countries. In summary, the trend in this transformation is one of a gradual decrease in internal research efforts and increasing reliance on external research. These empirical insights support the view that large pharmaceutical firms are increasingly becoming 'networks integrators' rather than the prime locus of drug discovery.-
dc.relation.isversionofPublisher's version-
dc.rightsopenAccess-
dc.subjectResearch network-
dc.subjectInnovation-
dc.subjectGlobalisation-
dc.subjectPharmaceuticals-
dc.subjectBibliometrics-
dc.subjectOutsourcing-
dc.subjectEurope-
dc.subjectCollaboration-
dc.titleBig Pharma, little science? A bibliometric perspective on big pharma's R&D decline-
dc.typecomunicación de congreso-
dc.relation.publisherversionhttp://druid8.sit.aau.dk/druid/registrant/index/papers-
dc.date.updated2014-11-14T10:39:31Z-
dc.description.versionPeer Reviewed-
dc.language.rfc3066eng-
dc.type.coarhttp://purl.org/coar/resource_type/c_5794es_ES
item.openairetypecomunicación de congreso-
item.fulltextWith Fulltext-
item.grantfulltextopen-
item.cerifentitytypePublications-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
Aparece en las colecciones: (INGENIO) Comunicaciones congresos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato
Big Pharma.pdf1,25 MBAdobe PDFVista previa
Visualizar/Abrir
Show simple item record

CORE Recommender

Page view(s)

333
checked on 05-may-2024

Download(s)

353
checked on 05-may-2024

Google ScholarTM

Check


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.